Browse > Article
http://dx.doi.org/10.3347/kjp.2013.51.4.393

Clinical Features and Treatment of Ocular Toxoplasmosis  

Park, Young-Hoon (Department of Ophthalmology and Visual Science, College of Medicine, The Catholic University of Korea)
Nam, Ho-Woo (Department of Parasitology, College of Medicine, The Catholic University of Korea)
Publication Information
Parasites, Hosts and Diseases / v.51, no.4, 2013 , pp. 393-400 More about this Journal
Abstract
Ocular toxoplasmosis is a disease caused by the infection with Toxoplasma gondii through congenital or acquired routes. Once the parasite reaches the retina, it proliferates within host cells followed by rupture of the host cells and invasion into neighboring cells to make primary lesions. Sometimes the restricted parasite by the host immunity in the first scar is activated to infect another lesion nearby the scar. Blurred vision is the main complaint of ocular toxoplasmic patients and can be diagnosed by detection of antibodies or parasite DNA. Ocular toxoplasmosis needs therapy with several combinations of drugs to eliminate the parasite and accompanying inflammation; if not treated it sometimes leads to loss of vision. We describe here clinical features and currently available chemotherapy of ocular toxoplasmosis.
Keywords
Toxoplasma gondii; ocular toxoplasmosis; retinal scar; blurred vision; diagnosis; treatment;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Holland GN. Ocular toxoplasmosis: a global reassessment. Part I: Epidemiology and course of disease. Am J Ophthalmol 2003; 136: 973-988.
2 Subauste CS, Ajzenberg D, Kijlstra A. Review of the series 'Disease of the year 2011: toxoplasmosis' pathophysiology of toxoplasmosis. Ocul Immunol Inflamm 2011; 19: 297-306.   DOI   ScienceOn
3 Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans. Int J Parasitol 2000; 30: 1217-1258.   DOI   ScienceOn
4 Dodds EM. Toxoplasmosis. Cur Opin Ophthalmol 2006; 17: 557-561.   DOI   ScienceOn
5 Bonfioli AA, Orefice F. Toxoplasmosis. Semin Ophthalmol 2004; 20: 129-141.
6 Garweg JG. Determinants of immunodiagnostic success in human ocular toxoplasmosis. Parasite Immunol 2005; 27: 61-68.   DOI   ScienceOn
7 Tugal-Tutkun I, Corum I, Otuk B, Urgancioglu M. Active ocular toxoplasmosis in Turkish patients: a report on 109 cases. Int Ophthalmol 2005; 26: 221-228.
8 Woods AC, Jacobs L, Wood RM, Cook MK. A study of the role of toxoplasmosis in adult chorioretinitis. Am J Ophthalmol 1954; 37: 163-177.
9 McCannel CA, Holland GN, Helm CJ, Cornell PJ, Winston JV, Rimmer TG. Causes of uveitis in the general practice of ophthalmology. UCLA Community-Based Uveitis Study Group. Am J Ophthalmol 1995; 121: 35-46.
10 Perkins ES. Ocular toxoplasmosis. Br J Ophthalmol 1972; 57: 1-17.
11 Glasner PD, Silveira C, Kruszon-Moran D, Martins MC, Junior MB, Silveira S, Camargo ME, Nussenblatt RB, Kaslow RA, Júnior RB. An unusually high prevalence of ocular toxoplasmosis in southern Brazil. Am J Ophthalmol 1992; 114: 136-144.
12 Holland GN. Ocular toxoplasmosis: new directions for clinical investigation. Ocul Immunol Inflamm 2000; 8: 1-7.   DOI   ScienceOn
13 Atmaca LS, Simsek T, Batioglu F. Clinical features and prognosis in ocular toxoplasmosis. Jpn J Ophthalmol 2003; 48: 386-391.
14 Park YH, Han JH, Nam HW. Clinical features of ocular toxoplasmosis in Korean patients. Korean J Parasitol 2011; 49: 167-171.   DOI   ScienceOn
15 Shimada K, O'Connor GR, Yoneda C. Cyst formation by Toxoplasma gondii (RH strain) in vitro. The role of immunologic mechanisms. Arch Ophthalmol 1974; 92: 496-500.   DOI
16 Silveira C, Belfort R, Burnier M, Nussenblatt R. Acquired toxoplasmic infection as the cause of toxoplasmic retinochoroiditis in families. Am J Ophthalmol 1988; 106: 362-364.   DOI
17 Silveira C, Vallochi AL, Rodrigues da Silva U, Muccioli C, Holland GN, Nussenblatt RB, Belfort R, Rizzo LV. Toxoplasma gondii in the peripheral blood of patients with acute and chronic toxoplasmosis. Br J Ophthalmol 2011; 95: 396-400.   DOI   ScienceOn
18 de Moura L, Bahia-Oliveira LM, Wada MY, Jones JL, Tuboi SH, Carmo EH, Ramalho WM, Camargo NJ, Trevisan R, Graça RM, da Silva AJ, Moura I, Dubey JP, Garrett DO. Waterborne toxoplasmosis, Brazil, from field to gene. Emerg Infect Dis 2006; 12: 326-329.   DOI
19 Gilbert RE, Stanford MR. Is ocular toxoplasmosis caused by prenatal or postnatal infection? Br J Ophthalmol 2000; 84: 224-226.   DOI
20 Brezin AP, Kasner L, Thulliez P, Li Q, Daffos F, Nussenblatt RB, Chan CC. Ocular toxoplasmosis in the fetus. Immunohistochemistry analysis and DNA amplification. Retina 1993; 14: 19-26.
21 Park YH. Toxoplasma gondii in the peripheral blood of patients with ocular toxoplasmosis. Br J Ophthalmol 2012; 96: 766.
22 Norose K, Mun HS, Aosai F, Chen M, Piao LX, Kobayashi M, Iwakura Y, Yano A. IFN-γ-regulated Toxoplasma gondii distribution and load in the murine eye. Invest Ophthalmol Vis Sci 2003; 44: 4375-4381.   DOI   ScienceOn
23 Schuman JS, Weinberg RS, Ferry AP, Guerry RK. Toxoplasmic scleritis. Ophthalmology 1988; 95: 1399-1403.   DOI
24 Smith JR, Franc DT, Carter NS, Zamora D, Planck SR, Rosenbaum JT. Susceptibility of retinal vascular endothelium to infection with Toxoplasma gondii tachyzoites. Invest Ophthalmol Vis Sci 2004; 45: 1157-1161.   DOI   ScienceOn
25 Ryan SJ. Retina. 3rd ed. St. Louis, USA, Mosby. 2001, p 1531-1544.
26 Cochereau-Massin I, LeHoang P, Lautier-Frau M, Zerdoun E, Zazoun L, Robinet M, Marcel P, Girard B, Katlama C, Leport C. Ocular toxoplasmosis in human immunodeficiency virus-infected patients. Am J Ophthalmol 1992; 114: 130-135.
27 Dodds EM, Holland GN, Stanford MR, Yu F, Siu WO, Shah KH, Ten Dam-van Loon N, Muccioli C, Hovakimyan A, Barisani- Asenbauer T. Intraocular inflammation associated with ocular toxoplasmosis: relationships at initial examination. Am J Ophthalmol 2008; 146: 856-865.   DOI   ScienceOn
28 Garweg JG, Jacquier P, Boehnke M. Early aqueous humor analysis in patients with human ocular toxoplasmosis. J Clin Microbiol 2000; 38: 996-1001.
29 Delair E, Latkany P, Noble AG, Rabiah P, McLeod R, Brezin A. Clinical manifestations of ocular toxoplasmosis. Ocul Immunol Inflamm 2011; 19: 91-102.   DOI   ScienceOn
30 Noble A. Cataracts in congenital toxoplasmosis. J AAPOS 2007; 11:551-554.   DOI   ScienceOn
31 Montoya JG, Parmley S, Liesenfeld O, Jaffe GJ, Remington JS. Use of the polymerase chain reaction for diagnosis of ocular toxoplasmosis. Ophthalmology 1999; 106: 1554-1563.   DOI   ScienceOn
32 Holland GN, Lewis KG. An update on current practices in the management of ocular toxoplasmosis, Am J Ophthalmol 2002; 134: 102-114.   DOI   ScienceOn
33 Jasper S, Vedula SS, John SS, Horo S, Sepah YJ, Nguyen QD. Corticosteroids for ocular toxoplasmosis. Cochrane Database Syst Rev 2013 30; 4:C D007417.
34 de-la-Torre A, Stanford M, Curi A, Jaffe GJ, Gomez-Marin JE. Therapy for ocular toxoplasmosis. Ocul Immunol Inflamm 2011; 19: 314-320.   DOI   ScienceOn
35 Rothova A, Meenken C, Buitenhuis HJ, Brinkman CJ, Baarsma GS, Boen-Tan TN, de Jong PT, Klaassen-Broekema N, Schweitzer CM, Timmerman Z. Therapy for ocular toxoplasmosis. Am J Ophthalmol 1993; 115: 517-523.
36 Gilbert RE, See SE, Jones LV, Stanford MS. Antibiotics versus control for toxoplasma retinochoroiditis. Cochrane Database Syst Rev 2002; 1: CD002218.
37 Silveira C, Belfort R, Muccioli C, Holland GN, Victora CG, Horta BL, Yu F, Nussenblatt RB. The effect of long-term intermittent trimethoprim/ sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am J Ophthalmol 2002; 134: 41-46.   DOI   ScienceOn
38 Holland GN. Prospective, randomized trial of trimethoprim/ sulfamethoxazole vs. pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis: discussion. Ophthalmology 2005; 112: 1882-1884.   DOI   ScienceOn
39 Soheilian M, Ramezani A, Azimzadeh A, Sadoughi MM, Dehghan MH, Shahghadami R, Yaseri M, Peyman GA. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology 2011; 118: 134-141.   DOI   ScienceOn
40 Soheilian M, Sadoughi MM, Ghajarnia M, Dehghan MH, Yazdani S, Behboudi H, Anisian A, Peyman G A. Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Ophthalmology 2005; 112: 1876-1882.   DOI   ScienceOn
41 Yang HJ, Jin KN, Park YK, Hong SC, Bae JM, Lee SH, Choi HS, Hwang HS, Chung YB, Lee NS, Nam HW. Seroprevalence of toxoplasmosis in the residents of Cheju island, Korea. Korean J Parasitol 2000; 38: 91-93.   DOI   ScienceOn
42 Kishore K, Conway MD, Peyman G A. Intravitreal clindamycin and dexamethasone for toxoplasmic retinochoroiditis. Ophthalmic Surg Lasers 2001; 32: 183-192.
43 Fichera ME, Bhopale MK, Roos DS. In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii. Antimicrob Agents Chemother 1995; 39: 1530-1537.   DOI   ScienceOn
44 Ahn HJ, Cho PY, Ahn SK, Kim TS, Chong CK, Hong SJ, Cha SH, Nam HW. Seroprevalence of toxoplasmosis in the residents of Cheorwon-gun, Gangwon-do, Korea. Korean J Parasitol 2012; 50: 225-227.   DOI   ScienceOn